12 / 51
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
Neumol Pediatr 2016; 11 (2): 65 - 70
70
Acualización en el tratamiento de bronquitis aguda: menos es más
Database Syst Rev. 2012;2:CD004873
21. Cunningham S, Rodriguez A, Adams T, Boyd KA, Butcher I,
Enderby B. Bronchiolitis of Infancy Discharge Study (BIDS)
group. Oxygen saturation targets in infants with bronchiolitis
(BIDS): a double-blind, randomised, equivalence trial.
Lancet 2015;386:1041-8
22. González Martínez F, González Sánchez MI, Rodríguez
Fernández R. Clinical impact of introducing ventilation
with high flow oxygen in the treatment of bronchiolitis in a
paediatric ward. An Pediatr (Barc) 2013;78:210-5
23. Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JA. High-
flow nasal cannula therapy for infants with bronchiolitis.
Cochrane Database Syst Rev. 2014;1:CD009609
24. Jat KR, Chawla D. Surfactant therapy for bronchiolitis
in critically ill infants. Cochrane Database Syst Rev.
2012;9:CD009194
25. American Academy of Pediatrics Committee on Infectious
Diseases,American Academy of Pediatrics Bronchiolitis
Guidelines Committee .Update guidance for palivizumab
prophylaxis among infants and young children at increased
risk of hospitalization for respiratory syncytial virus
infection. Pediatr 2014;134:e620-e638
26. Lavoie PM, Solimano A, Taylor R, Kwan E, Claydon J,
Turvey SE, Marr N Outcomes of Respiratory Syncytial Virus
Immunoprophylaxis in Infants Using an Abbreviated Dosing
Regimen of Palivizumab.
JAMA Pediatr 2015 ;28:1-2
27. Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK,
Jensen KMM et al. Motavizumab treatment of infants
hospitalized with respiratory syncytial virus infection does
not decrease viral load or severity of illness. Pediatr Infect
Dis J. 2014 ;33:703-9
28. O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP,
Bellamy T et al Efficacy of motavizumab for the prevention
of RSV disease in healthy Native American infants: a Phase
3 randomized double-blind placebo-controlled trial. Lancet
Infect Dis 2015;15: 1398-408
29. Johnson LW, Robles J, Hudgins A, Osburn S, Martin D,
Thompson A. Management of bronchiolitis in the emergency
department: impact of evidence-based guidelines? Pediatr
2013;131 Suppl 1:S103-9
30. Ralston SL, Garber MD, Rice-Conboy E, Mussman GM,
Shadman KA, Walley SC et al. A Multicenter Collaborative to
Reduce Unnecessary Care in Inpatient Bronchiolitis. Pediatr
2016 ;137 :1-9
31. Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough
A, Heikkinen T et al Lower respiratory tract infection caused
by respiratory syncytial virus: current management and new
therapeutics. Lancet Respir Med 2015; 3:888-900
32. Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu
H et al . A Randomized, Blinded, Controlled, Dose-Ranging
Study of a Respiratory Syncytial Virus Recombinant Fusion
(F) Nanoparticle Vaccine in Healthy Women of Childbearing
Age. J Infect Dis. 2016 1;213 :411-22
33. Esposito S, Lelii M. Vitamin D and respiratory tract infections
in childhood. BMC Infect Dis. 2015; 15:487
34. McNally JD, Sampson M, Matheson LA, Hutton B, Little
J. Vitamin D receptor (VDR) polymorphisms and severe
RSV bronchiolitis: a systematic review and meta-analysis.
Pediatr Pulmonol. 2014;49:790-9
35. Moreno-Solís G, Fernández-Gutiérrez F, Torres-Borrego J,
Torcello-Gáspar R, Gómez-Chaparro Moreno JL, Pérez-
Navero JL. Low serum 25-hydroxyvitamin D levels and
bronchiolitis severity in Spanish infants. Eur J Pediatr.
2015; 174:365-72
36. Belderbos ME, Houben ML, Wilbrink B, Lentjes E, Bloemen
EM, Kimpen JL, Rovers M, Bont L. Cord blood vitamin D
deficiency is associated with respiratory syncytial virus
bronchiolitis. Pediatr 2011 ;127: e1513-20
37. Camargo Jr CA, Ingham T, Wickens K, Thadhani R, Silvers
KM, Epton MJ et al. Cord-blood 25-hydroxyvitamin D levels
and risk of respiratory infection, wheezing, and asthma.
Pediatr 2011;127:e180–7